Lung disease is where this field's honesty gets tested, so here is all of it.
Respiratory conditions, and COPD especially, are among the most aggressively marketed targets for stem cell clinics. They are also where the randomized evidence is most sobering. We could soften that. Instead we are going to show you the whole picture, because a company that quotes trials to you owes you the trials that went against it too.
Here is what the controlled research found, where a real signal exists, and what an honest review looks like.
Aurenza does not claim that regenerative medicine treats, cures, or reverses COPD or any respiratory condition.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
Respiratory disease, and COPD especially, is among the most aggressively marketed targets for stem cell clinics, so this page holds itself to the strictest standard in the set: the trials, all of them, including the ones that went against the field.
The landmark study is a placebo-controlled, randomized trial of mesenchymal stem cells in COPD published in Chest (2013): 62 patients with moderate to severe COPD received four monthly intravenous infusions of allogeneic MSCs or placebo with two years of follow-up. The therapy was safe, with no infusional toxicities and no deaths or serious adverse events attributed to it, and it significantly decreased C-reactive protein in patients who started with elevated levels. A post hoc analysis in Respiratory Research (2021) found that within the elevated-inflammation subgroup, CRP of 4 or higher, treated patients showed at least transient meaningful pulmonary and functional improvements, a hypothesis-generating result the authors frame exactly that way.
Where the lung research is genuinely active is acute inflammatory disease: a 2025 systematic review and meta-analysis in Stem Cell Research and Therapy pooled the trial base in acute respiratory distress syndrome across mortality and safety outcomes, a meta-analysis presented at CHEST02226-2/fulltext) found a significant reduction in all-cause mortality in COVID-19-induced ARDS, relative risk 0.76, with no increase in adverse events, and rigorous trials such as the phase 2b STAT study registered on ClinicalTrials.gov continue the work.
The Honest Line
Here is the sentence a marketing page would never print, and the reason this page is trustworthy: the randomized COPD trial found no significant differences in pulmonary function tests or quality-of-life indicators. Safety, yes; anti-inflammatory effects, yes; restored lung function in COPD, not demonstrated. Any clinic promising to regrow lung tissue or reverse emphysema is contradicting the published randomized evidence, and now you hold the citation. No study shows a guarantee it works every time, or that it will work for you.
Why This Is Exactly Where a Candidacy Review Comes In
If inflammation is where the genuine research signal lives, then knowing your inflammatory markers is the honest first question, and it is one a baseline review answers with numbers rather than hope, alongside a straight answer, including no, where the evidence does not support proceeding. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
What to Ask Any Provider
Which randomized trials in my condition are you relying on, and what did they actually find on lung function? What did the trials that went against you find? What exactly is being administered and why? What would make me a poor candidate? If the honest answer is that the evidence does not support this for my case, will you say so?
The Honest Limits
Individual results cannot be predicted or guaranteed. No cell therapy is FDA approved for COPD or chronic respiratory disease, and any procedure takes place in Mexico under COFEPRIS regulation. Continue all prescribed pulmonary care, and seek urgent help for worsening breathlessness, fever with productive cough, or oxygen desaturation.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.